Journal Article

A Proteomic Approach Identified TFEB as a Key Player in the Protective Action of Novel CB2R Bitopic Ligand FD22a against the Deleterious Effects Induced by β-Amyloid in Glial Cells

Chiellini, Grazia, Carnicelli, Vittoria, Zucchi, Riccardo, Manera, Clementina, Ferrisi, Rebecca, Polini, Beatrice, Lucacchini, Antonio, Zuccarini, Mariachiara, Ronci, Maurizio, Ricardi, Caterina, Giusti, Laura, Gado, Francesca, Zallocco, Lorenzo

2024

Overview

Neurodegenerative diseases (NDDs) are progressive multifactorial disorders of the nervous system sharing common pathogenic features, including intracellular misfolded protein aggregation, mitochondrial deficit, and inflammation. Taking into consideration the multifaceted nature of NDDs, development of multitarget-directed ligands (MTDLs) has evolved as an attractive therapeutic strategy. Compounds that target the cannabinoid receptor type II (CB2R) are rapidly emerging as novel effective MTDLs against common NDDs, such as Alzheimer’s disease (AD). We recently developed the first CB2R bitopic/dualsteric ligand, namely FD22a, which revealed the ability to induce neuroprotection with fewer side effects. To explore the potential of FD22a as a multitarget drug for the treatment of NDDs, we investigated here its ability to prevent the toxic effect of β-amyloid (Aβ25–35 peptide) on human cellular models of neurodegeneration, such as microglia (HMC3) and glioblastoma (U87-MG) cell lines. Our results displayed that FD22a efficiently prevented Aβ25–35 cytotoxic and proinflammatory effects in both cell lines and counteracted β-amyloid-induced depression of autophagy in U87-MG cells. Notably, a quantitative proteomic analysis of U87-MG cells revealed that FD22a was able to potently stimulate the autophagy–lysosomal pathway (ALP) by activating its master transcriptional regulator TFEB, ultimately increasing the potential of this novel CB2R bitopic/dualsteric ligand as a multitarget drug for the treatment of NDDs.

• Publisher: MDPI AG
• Subject: Alzheimer's disease / Amyloid beta-Peptides - metabolism / Amyloid beta-Peptides - toxicity / Autophagy / Autophagy - drug effects / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism / Brain research / Cannabinoid CB2 receptors / cannabinoid receptor type II (CBR2) / Cell Line, Tumor / Cell lines / Cytokines / Cytotoxicity / Glial cells / Glioblastoma / Glioma / Homeostasis / Humans / Inflammation / Kinases / Ligands / Microglia / Nervous system / Neurodegeneration / Neurodegenerative diseases / Neuroglia - drug effects / Neuroglia - metabolism / neuroinflammation / Neuronal-glial interactions / Neuroprotection / Physiology / Protein folding / Protein interaction / Proteins / proteomic / Proteomics / Proteomics - methods / Receptor, Cannabinoid, CB2 - metabolism / Scientific equipment and supplies industry / TFEB / β-Amyloid